Skip to main content
×
×
Home

Another triumph of hope over experience?: Revisiting… Treatment of the patient with long-term schizophrenia

  • Ann M. Mortimer
Abstract

Schizophrenia continues to challenge services: recent advances in antipsychotic drug treatment and psychosocial interventions are hindered by non-adherence, disengagement and substance misuse. Furthermore, new side-effect concerns attach to atypical drugs, and psychosocial interventions may be underresourced or of unproven benefit. It is important to address all issues with which patients, families and carers need assistance, and to take a well-informed, creative approach to pharmacological treatment, using medication according to individual patient need rather than mechanistic adherence to guidelines. Psychiatrists should be realistic in their expectations of patient outcome, accepting outcomes that fall short of recovery and imply long-term supportive care, and insisting that this care be available to their patients. Psychiatrists should support early diagnosis and intervention as being possibly the only means to alleviate the burden of long-term schizophrenia for patients, families and services.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Another triumph of hope over experience?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Another triumph of hope over experience?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Another triumph of hope over experience?
      Available formats
      ×
Copyright
References
Hide All
Abi-Dargham, A. (2002) Recent evidence for dopamine abnormalities in schizophrenia. European Psychiatry, 17, 341347.
Anonymous (2004) Atypical antipsychotics in schizophrenia. Drugs and Therapeutics Bulletin (August), 5760.
Arvanitis, L. A., Miller, B. G. & the Seroquel Trial Study Group (1997) Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry, 42, 233246.
Barnas, C., Stuppack, C. H., Miller, C. et al (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms, a double blind trial versus haloperidol. International Clinical Psychopharmacology, 7, 2327.
Bowles, T. M. & Levin, G. M. (2003) Aripiprazole: a new atypical antipsychotic drug. Annals of Pharmacotherapy, 37, 687694.
Buchanan, R. W., Kreyenbuhl, J., Zito, J. M. et al (2002) Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. American Journal of Psychiatry, 159, 10351043.
Buse, J. B. (2002) Metabolic side-effects of antipsychotics: focus on hyperglycaemia and diabetes. Journal of Clinical Psychiatry, 63 (suppl. 4), 3741.
Cowen, P. J. (2005) New drugs, old problems. Advances in Psychiatric Treatment, 11, 1927.
Czekalla, J., Kollach-Walker, S. & Beasley, C.M. (2001) Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. Journal of Clinical Psychiatry, 62, (suppl. 2), 3540.
Davis, J. M. (1975) Overview: maintenance therapy in psychiatry. 1: Schizophrenia. American Journal of Psychiatry, 132, 12371245.
Davis, J. M. & Casper, R. (1977) Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs, 14, 260282.
Drake, R. E., Essock, S. M., Shaner, A. et al (2001) Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services, 52, 469476.
Edwards, J. G. (2005) Newer v. older antidepressants in long-term pharmacotherapy. Revisiting… Prevention of relapse and recurrence of depression. Advances in Psychiatric Treatment, 11, 184194.
Gournay, K. (2005) The changing face of psychiatric nursing. Advances in Psychiatric Treatment, 11, 611.
Green, B. (2000) Focus on risperidone. Current Medical Research and Opinion, 16, 5765.
Henderson, D. C. (2002) Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs, 16, 7789.
Hunt, G. E., Bergen, J. & Bashir, M. (2002) Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophrenia Research, 54, 253264.
Hwang, T. J., Lin, S. K. & Lin, H.-N. (2001) Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. Journal of the Formosan Medical Association, 100, 811816.
Joffe, G., Appelberg, B. & Rimon, R. (1999) Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with predominantly negative symptoms: an open prospective pilot study. International Clinical Psychopharmacology, 14, 233238.
Kerwin, R. W. & Bolonna, A. (2005) Management of clozapine-resistant schizophrenia. Advances in Psychiatric Treatment, 11, 101106.
Kopelowicz, A., Zarate, R., Tripodis, K. et al (2000) Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. American Journal of Psychiatry, 157, 987993.
Lacro, J. P., Dunn, L. B., Dolder, C. R. et al (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry, 63, 892909.
Lane, H. Y., Chiu, W. C., Chou, J. C. et al (2000) Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. Journal of Clinical Psychiatry, 61, 209214.
Lerner, V., Libov, I., Kotler, M. et al (2004) Combination of atypical antipsychotic medication in the management of treatment resistant schizophrenia and schizoaffective disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 28, 8998.
Leucht, S., Pitschel-Walz, G., Abraham, D. et al (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research, 35, 5168.
Leucht, S., Kissling, W. & McGrath, J. (2004) Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry, 65, 177186.
Marder, S. R. & Meibach, R. C. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825835.
Margolese, H. C., Malchy, L., Negrete, J. C. et al (2002) Drug and alcohol use among patients with schizophrenia and related psychosis: levels and consequences. Schizophrenia Research, 67, 157166.
Moller, H.-J. (2000) Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiatrica Scandinavica, Supplementum, 400, 1722.
Mortimer, A. (1997) Treatment of the patient with long-term schizophrenia. Advances in Psychiatric Treatment, 3, 339346.
Mortimer, A. M. (2001) Pharmacological treatment approaches. In Managing Negative Symptoms of Schizophrenia (eds Mortimer, A. & Spence, S.) pp. 4759. London: Science Press.
Mortimer, A. M., Martin, C., Wheeler, J. A. et al (2003) Antipsychotic prescription in unipolar depression. 2: Withdrawing antipsychotics in unipolar, non-psychotic patients. Journal of Clinical Psychiatry, 64, 668672.
Munro, J., O'Sullivan, D., Andrews, C. et al (1999) Beyond pharmacovigilance: active monitoring of 2,760 patients receiving clozapine in the UK and Ireland. British Journal of Psychiatry, 175, 576580.
National Institute for Clinical Excellence (2002) Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia (Technology Appraisal Guidance no. 43). London: NICE.
Noordsy, D. L. & Green, A. I. (2003) Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Current Psychiatry Reports, 5, 340346.
Peuskens, J. & Link, C. G. G. (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandanavica, 96, 265273.
Pilling, S., Bebbington, P., Kuipers, E. et al (2002a) Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine, 32, 763782.
Pilling, S., Bebbington, P., Kuipers, E. et al (2002b) Psychological treatments in schizophrenia: II. Meta-analyses of randomized controlled trials of social skills training and cognitive remediation. Psychological Medicine, 32, 783791.
Raniwalla, J., Tweed, J. A., Dollfus, S. et al (1996) A comparison of an atypical (zotepine) and classical (haloperidol) antipsychotic in patients with acute exacerbation of schizophrenia. Schizophrenia Research, 18, 133.
Robinson, D. G., Woerner, M. G., McMeniman, M. et al (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 161, 473479.
Rosebush, P. I. (2004) Treatment of catatonia. In Catatonia: from Psychopathology to Neurobiology (eds Caroff, S. N., Mann, S. C., Francis, A. et al), pp. 141150. Washington, DC: American Psychiatric Publishing.
Rosenthal, M. H. & Bryant, S. L. (2004) Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clinical Neuropharmacology, 27, 3843.
Russell, J. M. & Mackell, J. A. (2001) Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs, 15, 537551.
Seivewright, N., McMahon, C. & Egleston, P. (2005) Stimulant use still going strong. Revisiting… Misuse of amphetamines and related drugs. Advances in Psychiatric Treatment, 11, 262269.
Sensky, T., Turkington, D., Kingdon, D. et al (2000) A randomized controlled trial of cognitive–behavioural therapy for persistent symptoms in schizophrenia resistant to medication. Archives of General Psychiatry, 57, 165172.
Silver, H. S. N. (1998) Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. Journal of Clinical Psychopharmacology, 18, 208211.
Singh, S. P. & Fisher, H. L. (2005) Early intervention in psychosis: obstacles and opportunities. Advances in Psychiatric Treatment, 11, 7178.
Siris, S. G. (1993) Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. British Journal of Psychiatry, 163 (suppl. 22), 6678.
Small, J. G., Clapper, M. H., Malloy, F. W. et al (2003) Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. Journal of Clinical Psychopharmacology, 23, 223228.
Song, F. (1997) Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. Journal of Psychopharmacology, 11, 6571.
Stahl, S. M. & Grady, M. M. (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry – Central Nervous System Agents, 11, 313327.
Swafford, C. D., Scheller-Gilkey, G., Miller, A. H. et al (2000) Double jeopardy: schizophrenia and substance abuse. American Journal of Drug and Alcohol Abuse, 26, 343353.
Taylor, D. M. & McAskill, R. (2000) Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatrica Scandinavica, 101, 416432.
Tiihonen, J., Hallikainen, T., Ryynanen, O.-P. et al (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biological Psychiatry, 54, 12411248.
Tsuang, J. & Fong, T. W. (2004) Treatment of patients with schizophrenia and substance abuse disorders. Current Pharmaceutical Design, 10, 22492261.
Wassef, A. A., Hafiz, N. G., Hampton, D. et al (2001) Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. Journal of Clinical Psychopharmacology, 21, 2126.
Weiden, P., Aquila, A. & Standard, J. (1996) Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry, 57 (suppl. 11), 5360.
Winterer, G. & Hermann, W. M. (2000) Valproate and the symptomatic treatment of schizophrenia spectrum patients. Pharmacopsychiatry, 33, 182188.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 1355-5146
  • EISSN: 1472-1481
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 1
Total number of PDF views: 9 *
Loading metrics...

Abstract views

Total abstract views: 53 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 16th August 2018. This data will be updated every 24 hours.

Another triumph of hope over experience?: Revisiting… Treatment of the patient with long-term schizophrenia

  • Ann M. Mortimer
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *